- Nov 5, 2018: Primordial Genetics Granted Two New US Patents

Primordial Genetics is proud to announce the issuance of two new patents by the United States Patent and Trademark Office. US patents 10,077,441 and 10,093,922 protect our unique genetic technology for creating microbes with improved production economics or enhanced tolerance of abiotic stress and toxic products.

Primordial Genetics has successfully applied its Function Generator technology to develop a variety of valuable traits in microbes, including increased stress & product tolerance, improved protein expression or solubility, ability to produce recalcitrant proteins, increased production rates, titers and yields of valuable primary or secondary metabolites, and enzymes with resistance to inhibitors, expanded substrate specificity or higher catalytic activity.

The two new patents significantly add to the company’s technology protections and greatly enhance our intellectual property position.

- Oct 1, 2018: Primordial Genetics Awarded National Institutes of Health “America’s Seed Fund” Grant

Company aims to discover and develop single-subunit RNA polymerases for efficient RNA manufacturing

The National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program, also known as America’s Seed Fund, has awarded Primordial Genetics, Inc, a synthetic biology company, a $224,693 grant to support the creation of innovative technologies that align with NIH’s mission to improve health and save lives. Primordial Genetics’ NIH award is supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health.

A key objective of the SBIR program is to translate promising technologies to the private sector and enable life-saving innovations to reach consumer markets. Primordial Genetics’ work will focus on improved RNA manufacturing methods for RNA therapeutics. Progress in the development of RNA-based vaccines RNA therapeutics and RNA –based agricultural applications has created an unmet demand for inexpensive and efficient RNA manufacturing methods capable of generating large quantities (g to ktons) of pure, molecularly uniform RNA. Many applications are using chemical modifications that serve to increase RNA stability and efficacy. The commonly used RNA polymerases fall short of the requirements for such a manufacturing process, necessitating the development of novel RNA manufacturing enzymes that can incorporate non-natural nucleotides into RNA efficiently and with high fidelity.

In this project, Primordial Genetics aims to express, purify and characterize known, but so-far untested single-subunit RNA polymerases that can be developed into specialized RNA manufacturing enzymes. The company will test a suite of enzymes representing the natural diversity of bacteriophage RNA polymerases, for their ability to meet the critical requirements for in vitro RNA synthesis, including efficient, high-yield RNA synthesis, incorporation of non-natural nucleotides and high RNA quality.

This research is a feasibility study for isolating and developing novel enzymes suitable for RNA manufacturing, and also for creating an enzyme development pipeline that can meet the varied needs for manufacturing a diversity of RNA sequences, sizes and chemical structures represented in RNA vaccines and RNA therapeutic products under development.

The SBIR and Small Business Technology Transfer (STTR) programs are one of the largest sources of early-stage capital for technology commercialization in the United States. These programs allow US-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization.

- Aug 14, 2018: IN THE PRESS -- "The Science 'Rebel' Who's Teaching Microbes to be More Productive"

On this episode of the J&J Innovation Podcast, we sit down with Helge Zieler, founder and President of Primordial Genetics, about his journey from studying Malaria in Africa to unleashing the power of microbes in San Diego.

- March 19, 2018 : Go Beyond Investing conducts due diligence on Primordial Genetics

Go Beyond Investing (https://go-beyond.biz/) is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.

The Go Beyond team has conducted a thorough non-technical due diligence of Primordial Genetics’ business model. The Go Beyond team worked with several experts in the field of synthetic biology to attain a high level of comfort regarding the technical and commercial viability of Primordial’s scientific innovation and bio-methionine first product. The due diligence process supported the commercial and market promise of Primordial’s technology and products in development. Go Beyond is prepared to make an initial investment in this company.

- Jan 1, 2018: Primordial Genetics receives NIH Grant: Synthetic biology E. coli strain development for expression of functional human GPCRs with roles in human disease

The principal aim of this project is to apply a novel synthetic biology approach to develop protein expression strains of the laboratory bacterium Escherichia coli that are suitable for producing functional G-protein-coupled receptor (GPCR) proteins.

GPCRs are diverse membrane proteins that are ubiquitous in the human body. They are involved in many physiological processes as well as many diseases and have been the most important drug targets in modern medicine. Efficient production of milligram quantities of functional GPCR is currently very difficult. Although E. coli is widely used for protein production, expressing functional GPCRs in E. coli is still challenging.

The novel E. coli expression host to be developed in this project will ignificantly accelerate the production of GPCRs and drug development work with this important class of human proteins. This project will not only have a broad impact in drug discovery across many diseases but also will provide the scientific community a valuable resource for structural biology research.

Contact PI: Xu, Karen.